Interims analysis of a prospective observational study on the use of cilostazol (Pletal) in daily clinical vascularsurgical practice;Interimsanalyse einer prospektiven Beobachtungsstudie zur Anwendung von Cilostazol (Pletal) in täglicher klinisch-gefäßchirurgischer Praxis: Signifikante Verbesserung von Gehstrecke und Lebensqualität bei Patienten mit peripher-arterieller Verschlusskrankheit (pAVK) StadiumIIb, jedoch nicht bei Rauchern, auch im gefäßchirurgischen Klientel

Zentralblatt fur Chirurgie - Zeitschrift fur Allgemeine, Viszeral- und Gefasschirurgie

Volumn 136, Issue 5, 2011, Pages 436-443

  Meyer, F ^a   Graf, D ^a   Weber, M ^a   Panteli, B ^a   Adolf, D ^a   Halloul, Z ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

AB index; arteriosclerosis; Cilostazol, Pletal; peripheral arterial occlusion disease; quality of life; walking distance

Indexed keywords

CILOSTAZOL; TETRAZOLE DERIVATIVE; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG EFFECT; EXERCISE TEST; FEMALE; FOLLOW UP; GERMANY; HUMAN; MALE; MIDDLE AGED; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROSPECTIVE STUDY; QUALITY OF LIFE;

ADULT; AGED; AGED, 80 AND OVER; ARTERIAL OCCLUSIVE DISEASES; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; TETRAZOLES; VASODILATOR AGENTS;

EID: 80054853273     PISSN: 0044409X     EISSN: 14389592     Source Type: Journal    
DOI: 10.1055/s-0031-1283741     Document Type: Article

References (33)

1. Holler D, Claes C, von der Schulenburg J M. Treatment costs and quality of life of patients with peripheral arterial occlusive disease The German perspective. Vasa 2004 33 145-153 (Pubitemid 39141714)
2. Schulte K L., Buschmann I. S3-Leitlinien zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (PAVK). Berlin Medical 2009 4 12-15
3. Huppert P, Tacke J, Lawall H. S3-Leitlinien zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit. Radiologe 2010 50 7-15
4. Huppert P, Adili F, Bauersachs R. Die S3-Leitlinien zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (PAVK). Hessisches Ärzteblatt 2010 2 85-102
5. Lawall H, Diehm C, Pittrow P. Leitlinien der Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (PAVK). Vasa 2009 38 1-72
6. Minar E, Schillinger M. TASCII Kommentar aus Sicht des Angiologen. Gefässmed 2007 4 14-17 (Pubitemid 47011775)
7. Norgren L, Hiatt W R., Dormandy J A. et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASCII). Eur J Vasc Endovasc Surg 2007 33 S1-S75 (Pubitemid 46068992)
8. Schrör K. Cilostazol ein neuer pharmakologischer Ansatz zur konservativen Behandlung der peripheren arteriellen Verschlusskrankheit. In: Amann-Vesti B R. Diehm C Goyen M Gröchenig E (Schriftleiter) Koppensteiner R Kröger K Lorenz E PM Zeller T Zotz R B. Hrsg Gefaessmedizin.Net. Berlin ABW Wissenschaftsverlag 2009 48-56
9. Hiatt G, (guest ed.). Cilostazol and the Management of Vascular Disease. Atherosclerosis Supplements 2006 6 1-52
10. Kimura Y, Tani T, Kanbe T et al. Effect of Cilostazol on Platelet Aggregation and Experimental Thrombosis. Arzneimittelforschung 1985 35 1144-1149 (Pubitemid 15030828)
11. Yasuda K, Sakuma M, Tanabe T. Hemodynamic Effect of Cilostazol on Increasing Peripheral Blood Flow in Arteriosclerosis Obliterans. Arzneimittelforschung 1985 35 1198-1200 (Pubitemid 15030837)
12. Tamai Y, Takami H, Nakahata R et al. Comparison of the Effects of Acetylsalicylic Acid, Ticlopidine and Cilostazol on Primary Hemostasis Using a Quantitative Bleeding Time Test Apparatus. Haemostasis 1999 29 269-276 (Pubitemid 30207456)
13. Kim J, Lee K S., Kim Y I. et al. A Randomized Crossover Comparative Study of Aspirin, Cilostazol and Clopidogrel in Normal Controls: Analysis With Quantitative Bleeding Time and Platelet Aggregation Test. J Clin Neurosci 2004 11 600-602 (Pubitemid 38916968)
14. Schrör K. The Pharmacology of Cilostazol. Diabetes Obes Metab 2002 4 14-19
15. Katakami Y, Nakao Y, Koizumi T et al. Regulation of Tumour Necrosis Factor Production by Mouse Peritoneal Macrophages: the Role of Cellular Cyclic AMP. Immunology 1988 64 719-724
16. Morishita R. A Scientific Rationale for the CREST Trial Results: Evidence for the Mechanism of Action of Cilostazol in Restenosis. Atheroscler Suppl 2005 6 41-46 (Pubitemid 43261539)
17. Abbas R, Chow C P., Browder N J. et al. In Vitro Metabolism and Interaction of Cilostazol With Human Hepatic Cytochrome P450 Isoforms. Hum Exp Toxicol 2000 19 178-184 (Pubitemid 30411779)
18. Suri A, Forbes W P., Bramer S L. Effects of CYP3A Inhibition on the Metabolism of Cilostazol. Clin Pharmacokinet 1999 37 61-68 (Pubitemid 30171188)
19. Amendt K, Hsu E, Gomer M et al. Die Rolle von Cilostazol in der Therapie der paVK. Gefässchirurgie 2008 13 171-178
20. Douglas J S., Holmes D R., Kereiakes D J. et al. Coronary Stent Restenosis in Patients Treated With Cilostazol. Circulation 2005 112 2826-2832 (Pubitemid 41641677)
21. Iida O, Nanto S, Uematsu M et al. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. J Vasc Surg 2008 48 144-149
22. Shinohara Y, Katayama Y, Uchiyama S et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010 9 959-968
23. Faxon D P., Creager M A., Smith Jr S C. et al. Atherosclerotic Vascular Disease Conference: Executive Summary: Atherosclerotic Vascular Disease Conference Proceeding for Healthcare Professionals From a Special Writing Group of the American Heart Association. Circulation 2004 109 2595-2604 (Pubitemid 38720563)
24. Thompson P D., Zimet R, Forbes W P. et al. Meta-Analysis of Results From Eight Randomized, Placebo-Controlled Trials on the Effect of Cilostazol on Patients With Intermittent Claudication. Am J Cardiol 2002 90 1314-1319 (Pubitemid 35449476)
25. Regensteiner J G., Ware J E. Jr, McCarthy W J. et al. Effect of Cilostazol on Treadmill Walking, Community-Based Walking Ability, and Health-Related Quality of Life in Patients With Intermittent Claudication Due to Peripheral Arterial Disease: Meta-Analysis of Six Randomized Controlled Trials. J Am Geriatr Soc 2002 50 1939-1946 (Pubitemid 35462438)
26. ODonnell M E., Badger S A., Sharif M A. et al. The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. J Vasc Surg 2009 49 1226-1234
27. Sorkin E M., Markham A. Cilostazol. Drugs Aging 1999 14 63-71 discussion 72-73 (Pubitemid 29050247)
28. Beebe H G., Dawson D L., Cutler B S. et al. A New Pharmacological Treatment for Intermittent Claudication: Results of a Randomized, Multicenter Trial. Arch Intern Med 1999 159 2041-2050 (Pubitemid 29453592)
29. Money S R., Herd J A., Isaacsohn J L. et al. Effect of Cilostazol on Walking Distances in Patients With Intermittent Claudication Caused by Peripheral Vascular Disease. J Vasc Surg 1998 27 267-274 discussion 274-275
30. Bramer S L., Forbes W P. Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cilostazol. Clin Pharmacokinet 1999 37 25-32 (Pubitemid 30171184)
31. Regensteiner J G., Hiatt W R. Current Medical Therapies for Patients With Peripheral Arterial Disease: a Critical Review. Am J Med 2002 112 49-57 (Pubitemid 34113855)
32. Mukherjee D, Yadav J S. Update on Peripheral Vascular Diseases: From Smoking Cessation to Stenting. Cleve Clin J Med 2001 68 723-733 (Pubitemid 32744530)
33. Pratt C M. Analysis of the Cilostazol Safety Database. Am J Cardiol 2001 87 28D-33D